Repros Therapeutics (RPRX -1%) says the FDA has scheduled a meeting to discuss the Phase 2 tests...


Repros Therapeutics (RPRX -1%) says the FDA has scheduled a meeting to discuss the Phase 2 tests for its low dose oral Proellex treatment for endometriosis. The teleconference will be held during the last week of August.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs